MedTrace Logo

TAS Test: Online Motor-cognitive Tests for Early Detection of Alzheimer's Disease

NCT05194787 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2023-10-30

No results posted yet for this study

Summary

Global dementia prevalence is rising. Alzheimer's disease (AD), the most common cause, has devastating effects on people's quality of life. AD has a preclinical (pre-AD) period of 10-20 years when brain pathology silently progresses before any cognitive symptoms appear. Current tests for pre-AD are invasive, costly and unsuitable for screening at population level. Similar to screening for pre-diabetes and carcinoma in situ, it is important to detect AD at the preclinical stage in order to offer early interventions before the pathology progresses to the irrerversible degenerative stage. In the study, research will develop a new scalable test (TAS Test) by combining two innovative ideas: hand-movement tests to detect pre-AD \>10 years before cognitive symptoms begin; and computer vision so people can "self-test" online using home computers. This unique approach builds on recent discoveries that hand-movement patterns change in pre-AD. The research team will use exquisitely precise computer vision methods to automatically analyse movement data from thousands of participants, and combine this with machine learning of overall motor-cognitive performance. The project team has access to 3 well-phenotyped cohorts, \>10,000 existing participants and a cutting-edge assay for a blood AD biomarker, ptau181. The research team will develop a TAS Test algorithm to classify hand-movement and cognitive test data for pre-AD risk (p-taua181 levels) and determine TAS Test's precision to prospectively predict 5-year risks of cognitive decline and AD.

Conditions

  • Alzheimer Disease
  • Dementia
  • Age-related Cognitive Decline

Interventions

DIAGNOSTIC_TEST

Cognitive test scores, clinical diagnosis and blood biomarkers

Clinical diagnosis of Alzheimer's disease, mild cognitive impairment or normal ageing. Cognitive test score on CANTAB Blood biomarker (p-tau 181) level

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • University of Sydney

    collaborator OTHER

  • University of Leeds

    collaborator OTHER

  • University of Tasmania

    lead OTHER

Principal Investigators

  • Prof Vickers, PhD DSc · University of Tasmania

  • A/Prof Bai, PhD MSc · University of Tasmania

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-05
Primary Completion
2025-12-31
Completion
2030-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05194787 on ClinicalTrials.gov